US5739157A - Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase - Google Patents

Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase Download PDF

Info

Publication number
US5739157A
US5739157A US08/682,526 US68252696A US5739157A US 5739157 A US5739157 A US 5739157A US 68252696 A US68252696 A US 68252696A US 5739157 A US5739157 A US 5739157A
Authority
US
United States
Prior art keywords
crystalline
mixture
diastereoisomer
sss
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/682,526
Other languages
English (en)
Inventor
Stephen John Pegg
George Joseph Sependa
Elwyn Peter Davies
Chris Allan Veale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421550A external-priority patent/GB9421550D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Assigned to ZENECA LIMITED reassignment ZENECA LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VEALE, CHRIS ALLAN, DAVIES, ELWYN PETER, SEPENDA, GEORGE JOSEPH, PEGG, STEPHEN JOHN
Priority to US09/013,853 priority Critical patent/US5907043A/en
Application granted granted Critical
Publication of US5739157A publication Critical patent/US5739157A/en
Priority to US09/253,659 priority patent/US6037363A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to pyrrolidine derivatives, and more particularly the compound (S)-1- (S)-2-(4-methoxybenzamido)-3-methylbutyryl!-N- (S)-2-methyl-1-(trifluoroacetyl)propyl!pyrrolidine-2-carboxamide, shown by the formula I (set out hereinafter) ##STR1## and having the S configuration at the chiral centres identified by the symbols * and #, and solvates thereof, which compound is an inhibitor of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), which is of value, for example, as a research tool in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated.
  • HLE human leukocyte elastase
  • HNE human neutrophil elastase
  • HLE has been implicated causally in the pathogenesis of acute respiratory distress syndrome (ARDS), rheumatoid arthritis, atherosclerosis, pulmonary emphysema, and other inflammatory disorders, including airway inflammatory diseases characterized by increased and abnormal airway secretion such as acute and chronic bronchitis and cystic fibrosis.
  • ARDS acute respiratory distress syndrome
  • rheumatoid arthritis arthritis
  • atherosclerosis CAD
  • pulmonary emphysema pulmonary emphysema
  • other inflammatory disorders including airway inflammatory diseases characterized by increased and abnormal airway secretion such as acute and chronic bronchitis and cystic fibrosis.
  • HLE has been causally implicated in certain vascular diseases and related conditions (and their therapy) in which neutrophil participation is involved or implicated, for example, in hemorrhage associated with acute non-lymphocytic leukemia, as well as in reperfusion injury associated with, for example, myocardial ischaemia and related conditions associated with coronary artery disease such as angina and infarction, cerebrovascular ischaemia such as transient ischaemic attack and stroke, peripheral occlusive vascular disease such as intermittent claudication and critical limb ischaemia, venous insufficiency such as venous hypertension, varicose veins and venous ulceration, as well as impaired reperfusion states such as those associated with reconstructive vascular surgery, thrombolysis and angioplasty.
  • myocardial ischaemia and related conditions associated with coronary artery disease such as angina and infarction
  • cerebrovascular ischaemia such as transient ischaemic attack and stroke
  • peripheral occlusive vascular disease such as intermittent
  • the invention also concerns methods of treating one or more of these disease conditions and the use of the compound (or a solvate thereof) in the manufacture of a medicament for use in one or more of said conditions.
  • the invention further concerns pharmaceutical compositions containing the compound, or a solvate thereof, as active ingredient, as well as processes for the manufacture of the compound (or a solvate thereof), novel intermediates useful in said processes and methods for the preparation of said intermediates.
  • HLE inhibitor which cannot be isolated in a crystalline form as, or in the formulation of, a medicament for treating the disease conditions referred to above, poses significant problems, for example, in the manufacture of the compound or formulation to the purity levels and uniformity required for regulatory approval. It is therefore highly desirable to find a novel crystalline HLE inhibitor and even more desirable to obtain a novel crystalline HLE inhibitor which is a single diastereoisomer.
  • a further advantage of the compound of the invention is that it has been found to possess HLE inhibitory activity when administered orally. Prior to the present invention, the specific pyrrolidine derivative named above had not previously been prepared and therefore nothing was specifically known of its physical, chemical or pharmacological properties.
  • FIG. 1 shows an X-ray powder diffraction spectrum of a typical sample of the SSS diastereoisomer of formula I when it is substantially or essentially free of solvent.
  • FIG. 2 shows an X-ray powder diffraction spectrum of a typical sample of the SSS diastereoisomer of the formula I when it is approximately a 1:1 mixture of anhydrous and hydrated forms.
  • FIG. 3 shows an X-ray powder diffraction spectrum of a typical sample of the SSS diastereoisomer of the formula I when it is in a hydrated (gem-diol monohydrate) form.
  • FIG. 4 shows the infra red-spectrum of a sample of the SSS diastereoisomer of the formula I when it is substantially or essentially free of solvent.
  • the compound of the invention which may also be represented by the formula Ia ##STR2## (in which a thickened line denotes a bond projecting in front of the plane of the paper) is a single diastereoisomer, hereinafter referred to as the "SSS diastereoisomer of formula I” or the “SSS diastereoisomer", to distinguish it from other possible diastereoisomers with different configurations at the chiral centres indicated by * and # in formula I, for example, the diastereoisomer which, in formula I, has the S configuration at the chiral centres marked * and the R configuration at the chiral centre marked # (hereinafter referred to as the "SSR diastereoisomer of formula I" or the “SSR diastereoisomer”).
  • the SSS diastereoisomer of formula I is a crystalline solid, which exists in a form which is substantially or essentially free of solvent (hereinafter referred to as the "anhydrous" form), or as a solvated form.
  • the solvated form may, for example, be a hydrated form, which may exist as a gem-diol of the trifluoroketone functionality, that is as a compound of the formula Ib ##STR3## and/or a form which incorporates a water molecule as part of the crystal lattice.
  • the gem-diol Ib may itself be further hydrated.
  • Crystalline SSS diastereoisomer may be obtained in which the ratio of anhydrous form to solvated (for example, hydrated) form is, for example, about 1:1 or greater, such as 4:1 or greater.
  • the ratio of anhydrous form to solvated (for example, hydrated) form is, for example, about 19:1 or better, that is 95% or more by weight of the compound is in the anhydrous form.
  • the present invention therefore includes a crystalline form of the SSS diastereoisomer of formula I, or solvate thereof, which contains other possible diastereoisomers with different configurations at the chiral centres indicated by * and # in formula I. It has been found that crystalline SSS diastereoisomer of formula I, or a solvate thereof, can be obtained which contains 25% or less of the SSR diastereoisomer of formula I, that is the crystalline material has a ratio of SSS:SSR forms of about 3:1 or more.
  • the present invention therefore includes a crystalline form of the compound of formula I with a content of at least 75% of the SSS diastereoisomer.
  • crystalline material having a ratio of SSS:SSR of about 4:1 (or greater) and a ratio of anhydrous:hydrated forms of about 4:1 (or greater) can be obtained.
  • the crystalline SSS diastereoisomer of formula I, or a solvate thereof is substantially or essentially pure, i.e.
  • the SSR diastereoisomer of formula I contains less than 5% of one or more of the other possible diastereoisomers, for example, it contains less than 5% of the SSR diastereoisomer of formula I, preferably less than 3% of the SSR diastereoisomer of formula I, and more preferably less than 2% of the SSR diastereoisomer of formula I.
  • the SSS diastereoisomer of formula I is in the anhydrous form, i.e. substantially or essentially free of the solvated (for example, hydrated) form.
  • the SSS diastereoisomer has the advantageous property that it is non-hygroscopic. It also possesses the advantageous property that in the solid state it has good epimeric stability.
  • a particularly preferred form of the SSS diastereoisomer of formula I is a form containing less than 2% of the SSR diastereoisomer of formula I and being 95% or more in the anhydrous form.
  • the melting point of the SSS diastereoisomer of formula I generally depends on the level of purity and may be determined by conventional procedures well known in the art, for example, by differential scanning calorimetry (DSC).
  • the SSS diastereoisomer of formula I has a melting point which is in the range 147°-151° C., for example about 148°-150° C., in particular about 147°-149° C., when it is substantially or essentially in the anhydrous form and substantially or essentially free of the SSR diastereoisomer (heating rate 5° C./minute).
  • it may be obtained in a form having typically a melting point of about 116°-117° C.
  • the SSS diastereoisomer of formula I may be obtained in a crystalline hydrated form which is substantially or essentially free of the SSR diastereoisomer and which by differential scanning calorimetry (heating rate 2° C./minute) has an endothermic event with onset at about 91°-92° C. (with a peak at about 99°-100° C.), followed by an exothermic event with onset at about 109°-110° C. (with a peak at about 111°-112° C.), followed by a further endothermic event with onset at about 148°-149° C. (with a peak value at about 150°-151° C.).
  • the DSC data together with thermogravimetric analysis (TGA) data and 19 F NMR spectral data, indicate that this form is substantially the monohydrate of the gem-diol (of formula Ib).
  • TGA thermogravimetric analysis
  • 19 F NMR spectral data indicate that this form is substantially the monohydrate of the gem-diol (of formula Ib).
  • TGA thermogravimetric analysis
  • the X-ray powder diffraction spectra were determined using Scintag XDS-2000 X-ray diffractometer, with an EC&G solid-state photon detector, GLP Series (germanium) operated by a Microvax computer and using the Diffraction Management System software supplied by Scintag Inc., Sunnydale, Calif., USA.
  • the X-ray tube used was a Cu K-alpha with a wavelength of 1.5406A at 45 KV and 40 mA.
  • the receiving slits were set at 2 and 4 mm and the diverging slits set at 0.5 and 0.2 mm with respect to the path of the incident beam.
  • the spectra were obtained in the continuous scan mode with a chopper increment of 0.02. Each sample was exposed at 1 degree 2-theta per minute (running time was 38 minutes) and collected from 2 to 40 degrees 2-theta, to produce a trace of spacings against intensity for this range.
  • the samples were packed into round aluminium alloy sample pans with a diameter of 25 mm and depth of 2 mm.
  • the powder sample was placed in the pan so that an amount in excess of the pan volume was present and subsequently leveled to the pan rim with a glass microscope slide.
  • Silicon type-NBS 640b was used as an external standard.
  • Infra-red spectra were obtained for typical samples of the SSS diastereoisomer of the formula I when it is substantially or essentially free of solvent, when it is approximately a 1:1 mixture of anhydrous and hydrated forms, and when it is the monohydrate of formula Ib.
  • the infra-red spectra were obtained by the solvent cast technique well known in the art, from acetonitrile castings of a sample onto a salt (e.g. ZnSe or KBr) window for analysis by direct transmission.
  • the infra-red spectra were determined over the wave number range 4000 to 400 cm -1 .
  • the infra red-spectrum of a sample of the SSS diastereoisomer of the formula I when it is substantially or essentially free of solvent is shown in FIG. 4.
  • the spectrum of FIG. 4 includes sharp peaks at about 2968, 1761, 1629, 1607, 1533, 1503, 1443, 1259, 1209, 1178, 1158, 1032, 845 and 767 cm -1 .
  • the infra-red spectrum of a sample of the SSS diastereoisomer of the formula I when it is approximately a 1:1 mixture of anhydrous and hydrated forms, and that of a sample of the monohydrate of the gem-diol of formula Ib, were not significantly different to that of FIG. 3 due to the nature of the solvent cast technique and the solvent employed.
  • the hydrogen atoms of the hydroxyl groups of the gem-diol of formula Ib are acidic and that such compounds may therefore form crystalline pharmaceutically-acceptable salts, using conventional procedures, for example with bases affording physiologically-acceptable cations, for example alkali metal (such as sodium or potassium), alkali earth metal or organic amine salts.
  • the invention therefore includes crystalline pharmaceutically-acceptable salts of a gem-diol of formula Ib or a hydrate thereof.
  • SSS diastereoisomer of formula I may be obtained, by the following processes, which are further separate aspects of the invention.
  • Crystalline SSS diastereoisomer containing less than 25% SSR diastereoisomers may be obtained from a non-crystalline (amorphous) diastereomeric mixture of the SSS and SSR diasteroisomers, containing the SSS and SSR diastereoisomers in approximately equal amounts (i.e.
  • a ratio of about 1:1 to about 3:2 SSS:SSR by crystallisation from a suitable non-polar solvent, such as diethyl ether, di-n-propyl ether or di-n-butyl ether, or a mixture of solvents, such as a mixture of methyl tert-butyl ether and hexane or, preferably, a mixture of ethyl acetate and hexane.
  • a suitable non-polar solvent such as diethyl ether, di-n-propyl ether or di-n-butyl ether, or a mixture of solvents, such as a mixture of methyl tert-butyl ether and hexane or, preferably, a mixture of ethyl acetate and hexane.
  • One preferred such crystallisation process comprises reducing the volume of the solution of a non-crystalline diastereomeric mixture of the SSS and SSR diastereoisomers in ethyl acetate by evaporation or distillation, adding hexane to the hot solution and maintaining a clear solution, seeding with substantially pure SSS diastereoisomer and allowing to cool gradually.
  • a modification of this process includes the use of a solution of the non-crystalline diastereomeric mixture of the SSS and SSR diastereoisomers in a lower boiling solvent to that of ethyl acetate (such as methyl tert-butyl ether), for example as may be obtained directly from the work-up of the preparation of the non-crystalline mixture (as discussed below) and swapping the solvent for ethyl acetate by adding ethyl acetate and concentrating the solution by evaporation or distillation at atmospheric pressure, prior to the addition of the hexane.
  • ethyl acetate such as methyl tert-butyl ether
  • the product may be initially isolated as a mixture of anhydrous and hydrated diastereoisomers, for example, having a ratio of anhydrous:hydrated forms of about 1:1 or greater. Crystalline product having a ratio of anhydrous:hydrated forms of about 4:1 may, for example, be obtained.
  • Substantially or essentially pure crystalline SSS diastereoisomer of formula I may be obtained by repeated recrystallisation of crystalline SSS diasteroisomer containing SSR diastereoisomer.
  • a non-polar solvent which forms an azeotrope with water is generally employed for this purpose. This facilitates the removal of water from the system when the SSS diastereoisomer of formula I, containing SSR diastereoisomer, is dissolved by heating or boiling in a solvent of crystallisation, preferably with concentration of the solution, prior to addition of a second solvent if required, and allowing crystallisation to take place.
  • Toluene is a particularly suitable solvent for this purpose, or a mixture of ethyl acetate and hexane in which the hexane is added after azeotropic removal of water from the ethyl acetate solution.
  • Crystalline SSS diastereoisomer which is substantially or essentially pure and substantially or essentially in the anhydrous form may subsequently also be recrystallised from alternative solvents, including n-butyl acetate, isopropyl acetate, 1,2-dimethoxyethane, 2,2-dimethoxypropane, tert-butanol, tert-amyl methyl ether and mixtures of dichloromethane and hexane, methyl ethyl ketone and hexane, N,N-dimethylformamide and methyl tert-butyl ether, dipropyl ether and acetonitrile, 1,4-dioxane and hexane, methyl ethyl ketone and isohexane, tetrahydrofuran and cyclohexane, ethyl acetate and isohexane, tetrahydrofuran and hexane,
  • a substantially or essentially pure hydrated form (which data indicates to be a gem-diol monohydrate) may be obtained by repeated recrystallisation of crystalline SSS diastereoisomer containing SSR diastereoisomer using a mixture of acetone and water or a mixture of tert-butanol and water as solvent.
  • the ratio of volume of solvent (in ml) to weight of SSS diastereoisomer containing SSR diastereoisomer is, for example, in the range of 2:1 to 15:1, and conveniently about 6:1 to 10:1.
  • a non-crystalline (amorphous) diastereomeric mixture of SSS and SSR diastereoisomers as referred to above may be obtained as described in Example 20 of U.S. Pat. No. 4,910,190 or by the analogous process illustrated in Scheme 1.
  • novel process illustrated in Scheme 2 may be used, in which the novel intermediate N-(4-methoxybenzoyl)-L-valyl-L-proline (or a salt thereof), which is a further aspect of the invention, is coupled with 3-amino-4-methyl-1,1,1-trifluoro-2-pentanol, followed by conventional oxidation of the alcohol product to the corresponding ketone.
  • Conventional procedures for similar coupling and oxidation reactions are described herein and in U.S. Pat. No. 4,910,190.
  • An advantage of this process is that it allows incorporation of the aminoalcohol at a later stage.
  • the novel intermediate may be obtained using the conventional steps of selective deprotection, coupling and deprotection (Scheme 2, steps (a)-(c)), as illustrated in Procedure 1 hereinafter.
  • N-tert-butyloxycarbonylvaline is coupled with the proline benzyl ester, for example, using N-hydroxybenztriazole and dicyclohexylcarbodiimide in dichloromethane at 0° C., followed by removal of the tert-butyloxycarbonyl protecting group using trifluoroacetic acid to give L-valyl-L-proline benzyl ester.
  • the diastereomeric mixture obtained using these processes has an SSS:SSR ratio of about 1:1 to 3:2 and has only been isolated in a non-crystalline form, such as a foam or oil.
  • L-valyl-L-proline (or a salt thereof) with a tri(1-4C)alkylhalogenosilane, (for example, trimethylchlorosilane) or bis(tri(1-4C)alkylsilyl)acetamide (such as bis(trimethylsilyl)acetamide) to give L-valyl-L-proline tri(1-4C)alkylsilyl ester (for example L-valyl-L-proline trimethylsilyl ester); followed by
  • reaction of the L-valyl-L-proline tri(1-4C)alkylsilyl ester with an activated derivative of 4-methoxybenzoic acid for example, an acid chloride such as 4-methoxybenzoyl chloride (also known as anisoyl chloride) or an anhydride, to give N-(4-methoxybenzoyl)-L-valyl-L-proline tri(1-4C)alkylsilyl ester; followed by
  • Step (i) is conveniently carried out in a suitable inert solvent or diluent, for example ethyl acetate, an ethereal solvent or diluent (such as tetrahydrofuran or dioxan) or a hydrocarbon solvent such as toluene, in the presence of an organic base such as, for example, triethylamine, pyridine or, preferably, N-methylmorpholine, or an inorganic base such as sodium or potassium carbonate.
  • a suitable inert solvent or diluent for example ethyl acetate, an ethereal solvent or diluent (such as tetrahydrofuran or dioxan) or a hydrocarbon solvent such as toluene
  • organic base such as, for example, triethylamine, pyridine or, preferably, N-methylmorpholine
  • an inorganic base such as sodium or potassium carbonate.
  • Step (ii) is carried out under anhydrous conditions using a conventional method.
  • 4-methoxybenzoyl chloride is used and similar conditions to step (i) are employed.
  • about one equivalent of acid chloride to one equivalent of base (or a slight excess) are used.
  • the product of step (i) is not isolated, but is reacted in situ by addition of a further equivalent of the same base as used in step (i), followed by one equivalent of the acid chloride.
  • Step (iii) is carried out using a conventional procedure for the deprotection of a silyl protecting group, for example by hydrolysis under aqueous conditions. Conveniently the silyl protecting group is removed during the work-up procedure of step (ii). It will be appreciated that other conventional silylating agents may be used in step (i) to form the corresponding silyl ester of L-valyl-L-proline, which may then be used in step (ii) and the silyl protecting group then removed as in step (iii).
  • steps (i)-(iii) may be followed by:
  • Step (iv) is carried out using a conventional method for coupling a carboxylic acid to an amine to form an amide linkage, such as those described in U.S. Pat. No. 4,910,190.
  • a chloroformate for example an alkyl chloroformate (such as isobutyl chloroformate) in the presence of a tertiary amine (such as triethylamine or, preferable N-methylmorpholine), in a suitable solvent or diluent, for example a chlorinated solvent or diluent such as dichloromethane, an ethereal solvent or diluent such as tetrahydrofuran or methyl tert-butyl ether, or a hydrocarbon solvent or diluent such as toluene.
  • a chloroformate for example an alkyl chloroformate (such as isobutyl chloroformate) in the presence of a tertiary amine (such as tri
  • a mixture of solvents or diluents may be used, for example a mixture of toluene and tetrahydrofuran.
  • the reaction is generally carried out at a temperature in the range, for example, -15° C. to 30° C. and preferably between -10° C. to 20° C.
  • a reverse addition of the preformed mixed anhydride to a slurry of the aminoalcohol, for example using methyl tert-butyl ether as solvent, may also be used.
  • Step (v) is carried out using a conventional oxidising agent for the conversion of a hydroxy group into a ketone group.
  • Suitable oxidising agents and conditions include, for example, the use of oxalyl chloride, dimethyl sulfoxide, and a tertiary amine; the use of acetic anhydride and dimethyl sulfoxide; the use of chromium trioxide pyridine complex in dichloromethane; the use of hypervalent iodine reagent, such as 1,1,1-triacetoxy-2,1-benzoxidol-3(3H)-one with trifluoroacetic acid in dichloromethane; the use of excess dimethylsulphoxide and a water soluble carbodiimide in the presence of dichloroacetic acid; or alkaline aqueous potassium permanganate solution.
  • Particularly suitable oxidising agents are the latter two named, especially alkaline aqueous potassium permanganate solution, for example a mixture of
  • 3-Amino-4-methyl-1,1,1-trifluoro-2-pentanol may be obtained as described in U.S. Pat. No. 4.910,190 or as illustrated in the Examples.
  • the amorphous material isolated may be crystallised to provide substantially or essentially pure crystalline SSS diastereoisomer as a mixture of anhydrous and hydrated forms (for example, if diethyl ether is used as solvent of crystallisation), or substantially the anhydrous form (for example, if the material is crystallised or recrystallised from toluene).
  • the oxidation may be carried out using analogous conditions to those described in step (v) above.
  • a particularly advantageous procedure for the manufacture of the SSS diastereoisomer of formula I is characterised by heating a non-crystalline (amorphous) diastereomeric mixture of SSS and SSR diastereoisomers of formula I with a suitable base, for example a tertiary base such as an N-(1-4C)alkylmorpholine (for example, N-methylmorpholine), an N-(1-4C)alkylpiperidine (for example N-ethylpiperidine), pyridine or pentaisopropylguanidine, in a suitable non-polar solvent or diluent, for example, methyl tert-butyl ether, hexane or, preferably, a mixture of hydrocarbons having a boiling point in the range 100°-120° C.
  • a suitable base for example a tertiary base such as an N-(1-4C)alkylmorpholine (for example, N-methylmorpholine), an N-(1-4C)al
  • This epimerisation/crystallisation process therefore allows conversion of SSR diastereoisomer into SSS diastereoisomer, or recycling of mother liquors enriched in the SSR diastereoisomer, to produce further amounts of SSS diastereoisomer.
  • the process therefore has an advantage that it may be carried out using either an SSS- or SSR-enriched diastereomeric mixture.
  • a preferred base for use in the epimerisation/crystallisation process is N-methylmorpholine.
  • the heating is generally carried out, for example, at a temperature in the range of 50°-130° C., and conveniently, for example, initially at the refluxing temperature of the solvent or diluent, prior to allowing the reaction mixture to cool gradually and crystallisation of the SSS diastereoisomer to take place. It is preferable that the reaction mixture is heated so that distillation of solvent occurs, prior to cooling.
  • a miscible non-polar solvent or diluent in which the SSS diastereoisomer is less soluble may be added to the heated solution to aid crystallisation. This addition may conveniently be carried out while distillation of the initial solvent or diluent is taking place, to prevent premature crystallisation of product.
  • the initial solvent in which the diastereomeric mixture and base are heated may be substantially replaced by a miscible non-polar solvent of higher boiling point in which the SSS diastereoisomer is less soluble, prior to gradual cooling.
  • a miscible non-polar solvent of higher boiling point in which the SSS diastereoisomer is less soluble prior to gradual cooling.
  • a miscible non-polar solvent of higher boiling point in which the SSS diastereoisomer is less soluble prior to gradual cooling.
  • a miscible non-polar solvent of higher boiling point in which the SSS diastereoisomer is less soluble prior to gradual cooling.
  • a miscible non-polar solvent of higher boiling point in which the SSS diastereoisomer is less soluble prior to gradual cooling.
  • crystallisation is carried out by allowing the temperature of the mixture to cool slowly to ambient temperature, for example by allowing the temperature to fall in 10° C. steps and maintaining at each temperature for about one hour.
  • Preferably 0.5-1 equivalent of base per equivalent of amorphous starting material is used, especially about 1 equivalent.
  • a modification of this epimerisation/crystallisation process which may be used to prepare the SSS diastereoisomer of formula I is crystallisation of a non-crystalline mixture of the SSS and SSR diastereoisomers from a suitable non-polar solvent (as referred to above), such as a mixture of ethyl acetate and hexane, in the presence of a catalytic amount (for example about 10 mole %) of a base (as defined above), for example N-methylmorpholine.
  • a suitable non-polar solvent as a mixture of ethyl acetate and hexane
  • the crystalline material initially isolated is crystalline SSS diastereoisomer containing less than 25% SSR diastereoisomer, for example crystalline material with a ratio of SSS:SSR of 4:1 or better is generally obtained.
  • the material is generally initially isolated as a mixture of anhydrous and hydrated forms.
  • Substantially or essentially pure crystalline SSS diastereoisomer of formula I, substantially or essentially in the anhydrous form, for example, containing about 5% or less of the hydrated form, or a crystalline hydrated form, may be obtained by recrystallisation of this material as described hereinbefore.
  • the potency of the compound of the invention to act as an inhibitor of human leukocyte elastase (HLE) on the low molecular weight peptide substrate methoxy-succinyl-alanyl-alanyl-prolyl-valine-p-nitroanilide is determined as described in U.S. Pat. No. 4,910,190.
  • the potency of the compound is evaluated by obtaining a kinetic determination of the dissociation constant, K i , of the complex formed from the interaction of the inhibitor with HLE.
  • the compound of the invention was found to have a Ki of 6.7 nM.
  • Animal models of emphysema include intratracheal (i.t.) administration of an elastolytic protease to cause a slowly progressive, destructive lesion of the lung. These lesions are normally evaluated a few weeks to a few months after the initial insult. However, these proteases also induce a lesion that is evident in the first few hours. The early lesion is first hemorrhagic, progresses to an inflammatory lesion by the end of the first 24 hours and resolves in the first week post insult. To take advantage of this early lesion, the following model may be used.
  • Hamsters are first lightly anesthetized with Brevital. Phosphate buffered saline (PBS) pH 7.4, either alone or containing human leukocyte elastase (HLE), is then administered directly into the trachea. Twenty-four hours later the animals are killed and the lungs removed and carefully trimmed of extraneous tissue. Following determination of wet lung weight, the lungs are lavaged with PBS and total lavagable red and white cells recovered are determined. The values for wet lung weights, total lavagable red cells and total lavagable white cells are elevated in a dose-dependent manner following administration of HLE.
  • PBS Phosphate buffered saline
  • HLE human leukocyte elastase
  • Compounds that are effective elastase inhibitors can prevent or diminish the severity of the enzyme-induced lesion resulting in lower wet lung weight and reduced values for total lavagable cells, both red and white, relative to administration of HLE alone.
  • Compounds can be evaluated by administering them intratracheally as solutions or suspensions in PBS, either with or at various times prior to the HLE challenge (400 ⁇ g), or by dosing them intravenously or orally as solutions at various times prior to the HLE challenge (100 ⁇ g) to determine their utility in preventing an HLE lesion.
  • a solution of the compound of the invention is conveniently prepared using 10% polyethylene glycol 400/PBS.
  • HNE human neutrophil elastase
  • the compounds are then dosed intravenously or orally to the hamsters at a fixed time, such as 30 or 90 min, prior to intratracheal administration of 50 ⁇ g/animal of HNE in 300 ⁇ L phosphate buffered saline (PBS) pH 7.4.
  • PBS phosphate buffered saline
  • the animals are killed with an overdose of pentobarbital sodium, the thorax opened and the lungs and heart removed and the lungs cleared of extraneous material.
  • the excised lungs are lavaged with three changes of 2 ml PBS via a tracheal cannula.
  • the recovered lavages are pooled, the volumes (about 5 mL) are recorded and the lavages stored at 4° C. until assayed.
  • the thawed lavages and a sample of whole hamster blood are sonicated to disrupt erythrocytes and appropriately diluted into individual wells of a 96-well microtiter plate.
  • the optical densities (OD) of the disrupted lavages and blood samples are determined at 540 nm.
  • the ( ⁇ L blood equivalents)/(mL lavage) are determined by comparing the OD of the test samples with the OD of the standard curve prepared from whole hamster blood.
  • the total ⁇ L equivalents of blood recovered is determined by multiplying recovered lavage volume by the ( ⁇ L blood equivalents)/(mL lavage) for each sample.
  • Results are reported as % inhibition of HNE-induced hemorrhage with respect to PBS treated controls when the test compound is given at a specified dose and time prior to administration of HNE.
  • the ED 50 for the compound of the invention was found to be 5.2 mg/kg after oral dosing and 0.59 mg/kg after i.v. administration.
  • a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of the invention, or a solvate thereof, and a pharmaceutically acceptable diluent or carrier.
  • another feature of the invention is a method of using the compound of the invention, or a solvate thereof, in the treatment of a disease or condition in a mammal, especially a human, in which HLE is implicated, such as those referred to hereinbefore, and particularly acute and chronic bronchitis, pulmonary emphysema, reperfusion injury, adult respiratory distress syndrome, cystic fibrosis, or peripheral vascular disease (such as critical limb ischaemia or intermittent claudication).
  • the compound of the present invention may be administered to a warm-blooded animal, particularly a human, in need thereof for treatment of a disease in which HLE is implicated, in the form of a conventional pharmaceutical composition, for example as generally disclosed in U.S. Pat. No. 4,910,190.
  • One mode of administration may be via a powdered or liquid aerosol.
  • the compound of the invention may be administered in the same manner as cromolyn sodium via a ⁇ Spinhaler ⁇ (a trademark) turbo-inhaler device obtained from Fisons Corp. of Bedford, Mass. at a rate of about 0.1 to 50 mg per capsule, 1 to 8 capsules being administered daily for an average human.
  • Each capsule to be used in the turbo-inhaler contains the required amount of the compound of the invention with the remainder of the 20 mg capsule being a pharmaceutically acceptable carrier such as lactose.
  • a pharmaceutically acceptable carrier such as lactose.
  • the compound of the invention may be administered using a nebulizer such as, for example, a ⁇ Retec ⁇ (trademark) nebulizer, in which the solution is nebulized with compressed air.
  • the aerosol may be administered, for example, at the rate of one to about eight times per day as follows: A nebulizer is filled with a solution of the compound, for example 3.5 mL of solution containing 10 mg/mL; the solution in the nebulizer is nebulized with compressed air; and the patient breathes normally (tidal volume) for eight minutes with the nebulizer in his mouth.
  • the mode of adminstration may be parenteral, including subcutaneous deposit by means of an osmotic pump or, preferably, oral.
  • the compound of the invention may be conventionally formulated in an oral or parenteral dosage form by compounding about 10 to 250 mg per unit of dosage with conventional vehicle, excipient, binder, preservative, stabilizer, flavor or the like as called for by accepted pharmaceutical practice, e.g. as described in U.S. Pat. No. 3,755,340.
  • a 1 to 10 mL intravenous, intramuscular or subcutaneous injection would be given containing about 0.02 mg to 10 mg/kg of body weight of the compound of the invention 3 or 4 times daily.
  • an aqueous formulation may be prepared, for example, by dissolving the compound in 5-10% polyethylene glycol 400/phosphate buffered saline, followed by aseptic filtration, and sterile storage using standard procedures.
  • the compound of the invention will be administered to humans at a daily dose in the range of, for example, 5 to 100 mg of the compound by aerosol or 50 to 1000 mg intravenously or orally, or a combination thereof.
  • a daily dose in the range of, for example, 5 to 100 mg of the compound by aerosol or 50 to 1000 mg intravenously or orally, or a combination thereof.
  • a solvated (for example, hydrated) form of the compound also may be used.
  • Protocols for the administration of an HLE inhibitor and evaluation of the patients are described in the European Patent Applications with Publication Numbers 458535, 458536, 458537, and 463811 for the treatment or prevention of cystic fibrosis, ARDS, bronchitis, and hemorrhage associated with acute non-lymphocytic leukemia or its therapy, respectively; and the compound of the invention may be used similarly, or preferably used by oral administration, for the treatment of those diseases and conditions either alone or in combination with another therapeutic agent customarily indicated for the treatment of the particular condition.
  • a compound of the invention may conveniently be administered by an oral or parenteral route, either alone or simultaneously or sequentially with other therapeutically active agents customarily administered for the condition.
  • the utility of the compound of the invention in such treatment of vascular diseases and related conditions may be demonstrated using the procedures described in International Patent Application, Publication No. WO 92/22309.
  • temperatures are given in degrees Celsius (°C.); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18°-25° C.;
  • chromatography means ⁇ flash chromatography ⁇ (method of Still) carried out on Merck Kieselgel (Art 9385 from E. Merck, Darmstadt, Germany), elution using both step and ramp gradients is denoted by the parenthetical term "gradient” followed by the initial and final solvent ratios; thin layer chomatography (TLC) was carried out on silica plates, for example 0.25 mm silica gel GHLF plates (Art 21521 from Analtech, Newark, Del., USA);
  • melting points are uncorrected and (dec) indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations;
  • NMR data when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm relative to tetramethylsilane (TMS) as an internal standard, determined at 250 MHz using DMSO-d 6 as solvent; conventional abbreviations for signal shape are used; for AB spectra the directly observed shifts are reported;
  • this material showed an initial change at about 149.5° C., with a peak at about 151° C.
  • the starting aminoalcohol was obtained as follows:
  • Trifluoroacetic acid 200 ml was added to a mixture of N-benzyloxycarbonyl-L-valyl-L-proline tert-butyl ester (80.0 g) in methylene chloride ((300 ml) at 0° C. over approximately 30 minutes. After stirring at 0° C. for one hour, the reaction mixture was allowed to rise to ambient temperature and stirred an additional 3 hours. The reaction mixture was then comcentrated under vacuum and reconcentrated four times from toluene to remove residual trifluoroacetic acid. The resulting viscous oil was dried under vacuum for 16 hours.
  • N-benzyloxycarbonyl-L-valyl-L-proline (A) (63.6 g) as a pale yellow viscous oil; NMR (d 6 -DMSO): 0.92 (2d, 6H), 1.65-2.05 (2m, 4H), 2.25 (m, 1H), 3.60 (m, 1H), 3.80 (m, 1H), 4.05 (dd, 1H), 4.25 (m, 1H), 5.02 (2d, 2H), 7.35 (m, 5H), 7.50 (d, 1H).
  • N-methylmorpholine (16.6 ml) was added in one portion to a stirred solution of compound A in tetrahydrofuran (THF; 550 ml) and the solution was cooled to -35° C.
  • Isobutyl chloroformate (18.9 ml) was then added dropwise to the cooled solution.
  • the reaction mixture was stirred for one hour and then a solution of 2(R),3(S)-3-amino-4-methyl-1,1,1-trifluoro-2-pentanol (24.5 g) in THF (160 ml) was added dropwise over 30 minutes. The reaction mixture was stirred for an additional hour at -35° C.
  • Triphosgene (23 g) was added in one portion to a well stirred mixture of 2(RS),3(SR)-3-amino-4-methyl-1,1,1-trifluoro-2-pentanol hemioxalate salt (50 g) in toluene (250 ml) and 2M sodium hydroxide solution (350 ml). The reaction began to exotherm and was placed in an ice bath. After 0.5 hour the reaction was warmed to 25° C. and TLC indicated a substantial amount of unreacted amine present. The pH of the solution was readjusted to about 12 using 50% sodium hydroxide solution. An additional portion of triphosgene (8 g) was added and the solution was stirred for 1 hour.
  • n-Butyllithium (20 ml of a 10M solution in hexane) was added to a solution of 4(RS), 5(SR)-4-isopropyl-5-trifluoromethyl-2-oxazolidinone (35.8 g) in THF (600 ml) at -78° C., followed by stirring for 0.5 hours.
  • (-)-Menthyl chloroformate (41 ml, freshly distilled) was added followed by continuation of stirring at -78° C. for 0.5 hours.
  • the solution was warmed to 25° C. and the reaction quenched by addition of saturated aqueous sodium bicarbonate solution.
  • the product was extracted into ether and washed with water and brine.
  • a non-crystalline (amorphous) diastereomeric mixture (foam or oil) of SSS and SSR diastereoisomers of formula I (0.5 g) in a ratio of about 1:1 was dissolved in diethyl ether (2.5 ml), seeded with a crystal of substantially pure SSS diastereoisomer, and allowed to stand for 16 hours.
  • the solid which crystallised was collected by filtration, washed with diethyl ether and allowed to dry to give crystalline SSS diastereoisomer containing SSR diastereoisomer, in 30-45% yield, (ratio SSS:SSR 88:12; anhydrous form:hydrated form 1:1). (A similar result was obtained when a non-crystalline diastereomeric mixture of SSS:SSR 3:2 was used.)
  • a non-crystalline diastereomeric mixture of SSS and SSR diastereoisomers of formula I (ratio SSS:SSR 48.5:51.5; 5.18 g) was dissolved in tert-butyl methyl ether (23 ml) and N-methylmorpholine (1.3 ml) was added. The mixture was heated to reflux and a mixture of hydrocarbons having a boiling point of 100°-120° C. (ESSOCHEM 30; 60 ml) was added slowly while maintaining the temperature of the reaction mixture at 98° C. After 25 ml of distillate was collected, the temperature was lowered to 70° C. and a few seed crystals of substantially pure SSS-diastereoisomer were added.
  • the reaction mixture was stirred at 70° C. for one hour, at 60° C. for a further hour, and finally at ambient temperature for 16 hours.
  • the resulting crystalline solid was collected by filtration, washed with ESSOCHEM 30 and allowed to dry to give a crystalline mixture of SSS and SSR diastereoisomers (4.8 g), having a ratio of SSS:SSR of 76:24.
  • This material was added to water (17 ml) with stirring and 2M hydrochloric acid (2 ml) was added. After stirring at ambient temperature for 90 minutes, the crystalline solid was collected by filtration, washed with water and dried (3.88 g). (This was shown by HPLC to have the same SSS:SSR ratio.)
  • a non-crystalline (amorphous) diastereomeric mixture of SSS and SSR diastereoisomers of formula I (29.4 g) in ethyl acetate (200 ml) was distilled at atmospheric pressure to remove 100 ml of distillate. Further ethyl acetate (166 ml) was then added and the solution again distilled at atmospheric pressure to remove 166 ml of distillate. This procedure was then repeated. The solution was then cooled to 60° C. and hexane (166 ml) was added over 30 minutes at 60° C. to give a clear solution.
  • the solution was cooled to 50° C., seeded with substantially pure crystalline SSS diastereoisomer (0.1 g) and allowed to cool to ambient temperature for 18 hours.
  • the mixture was stirred for a further 18 hours at 0° C., warmed to 20° C. and further hexane (33 ml) added over ten minutes. After stirring for 3 hours at ambient temperature further hexane (50 ml was added) and the mixture stirred for a further 18 hours at ambient temperature.
  • the crystalline product was collected by filtration and dried under vacuum for four hours to give a crystalline mixture of SSS and SSR diastereoisomers (39% yield) having a ratio of SSS:SSR of 85:15 by HPLC.
  • N-(4-methoxybenzoyl)-L-valyl-L-proline tert-butyl ester (B) was purified by silica chromatography, using methanol:methylene chloride (3:97) as eluant, to give N-(4-methoxybenzoyl)-L-valyl-L-proline tert-butyl ester (B) as a foam; NMR (300 MHz, d 6 -DMSO): 0.94 (d, 3H), 0.99 (d, 3H), 1.30 (s, 9H), 1.76 (m, 1H), 1.80 (m, 2H), 2.13 (m, 2H), 3.61 (m, 1H), 3.80 (s,3H), 3.93 (m, 1H), 4.17 (dd, 1H), 4.46 (t, 1H), 6.96 (d, 2H), 7.90 (d, 2H), 8.35 (d, 1H).
  • N-(4-methoxybenzoyl)-L-valyl-L-proline (6.5 g) (C) which was used without further purification;
  • NMR 300 MHz; d 6 -DMSO: 0.87 (d, 3H), 0.99 (d, 3H), 1.88 (m, 3H), 2.15 (m, 2H), 3.64 (m, 1H), 3.80 (s, 3H), 3.97 (m, 1H), 4.24 (dd, 1H), 4.44 (t, 1H), 6.96 (d, 2H), 7.90 (d, 2H), 8.37 (d, 1H).
  • step (v) was carried out as follows:
  • reaction mixture was poured into ethyl acetate and washed with 1M hydrochloric acid solution, saturated sodium bicarbonate, and brine.
  • the solution was dried (MgSO 4 ) and the solvent removed by evaporation to give a mixture of SSS and SSR diastereoisomers of formula I as an oil.
  • N-methylmorpholine 46 ml was added to a mixture of L-valyl-L-proline hydrochloride (34 g) in THF (850 ml), followed by trimethylchlorosilane (41 ml) maintaining the temperature below 30° C. The mixture was stirred for 2 hours and then cooled to 0° C. Further N-methylmorpholine (16.5 ml) was added, followed by a solution of 4-anisoyl chloride (18 ml) in THF (25 ml), maintaining the temperature below 5° C. After 15 minutes, the mixture was filtered and the filtrate concentrated in vacuo to a yellow oil.
  • the oil was dissolved in ethyl acetate (100 ml) and basified to pH 7-8 with saturated potassium bicarbonate solution (100 ml). The aqueous layer was separated and washed with ethyl acetate (50 ml). The aqueous layer was then acidified to pH 2-3 with 2M hydrochloric acid solution and extracted with ethyl acetate (150 ml). The organic extract was concentrated under vacuum and toluene (150 ml) was added. The solution was again concentrated under vacuum until about 50 ml of toluene was collected.
  • N-methylmorpholine 36.8 ml was added to a solution of N-(4-methoxybenzoyl)-L-valyl-L-proline (34.8 g) in THF (100 ml) and methyl tert-butyl ether (150 ml) and the mixture was cooled to -5° C.
  • a solution of isobutylchloroformate (14.4 ml) in methyl tert-butyl ether (30 ml) was added over 30 minutes, maintaining the temperature at -5° C. during the addition. The reaction mixture was stirred at -5° C.
  • the reaction mixture was stirred for a further hour at this temperature and then methanol (100 ml) was added and the mixture stirred for 2 hours at 5°-10° C.
  • the reaction mixture was filtered through diatomaceous earth and the filter cake washed with water (60 ml).
  • Sodium chloride (400 g) and methyl tert-butyl ether (200 ml) was added to the filtrate, the mixture stirred for 10 minutes and the organic phase separated.
  • the aqueous phase was extracted with methyl tert-butyl ether (50 ml) and the combined organic phases washed successively with 2M hydrochloric acid, water, sodium bicarbonate solution and brine.
  • the organic solution was dried (MgSO 4 ) and volatile material was removed by evaporation to give a diastereomeric mixture of SSS and SSR diastereoisomers of formula I as a foam (SSS:SSR ratio of about 1:1).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US08/682,526 1994-02-11 1995-02-07 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase Expired - Fee Related US5739157A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/013,853 US5907043A (en) 1994-02-11 1998-01-27 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
US09/253,659 US6037363A (en) 1994-02-11 1999-02-22 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9402680A GB9402680D0 (en) 1994-02-11 1994-02-11 Pyrrolidine derivatives
GB9402680 1994-02-11
GB9421550A GB9421550D0 (en) 1994-10-26 1994-10-26 Heterocyclic derivative
GB9421550 1994-10-26
PCT/GB1995/000242 WO1995021855A1 (en) 1994-02-11 1995-02-07 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/013,853 Division US5907043A (en) 1994-02-11 1998-01-27 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase

Publications (1)

Publication Number Publication Date
US5739157A true US5739157A (en) 1998-04-14

Family

ID=26304315

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/682,526 Expired - Fee Related US5739157A (en) 1994-02-11 1995-02-07 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
US09/013,853 Expired - Fee Related US5907043A (en) 1994-02-11 1998-01-27 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
US09/253,659 Expired - Fee Related US6037363A (en) 1994-02-11 1999-02-22 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase

Family Applications After (2)

Application Number Title Priority Date Filing Date
US09/013,853 Expired - Fee Related US5907043A (en) 1994-02-11 1998-01-27 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
US09/253,659 Expired - Fee Related US6037363A (en) 1994-02-11 1999-02-22 Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase

Country Status (20)

Country Link
US (3) US5739157A (sv)
EP (1) EP0743953B1 (sv)
JP (1) JP3416142B2 (sv)
CN (1) CN1140455A (sv)
AT (1) ATE174034T1 (sv)
AU (1) AU692515B2 (sv)
CA (1) CA2180006A1 (sv)
DE (1) DE69506380T2 (sv)
DK (1) DK0743953T3 (sv)
ES (1) ES2125004T3 (sv)
FI (1) FI963132A (sv)
GB (1) GB9402680D0 (sv)
HK (1) HK1011033A1 (sv)
IL (1) IL112613A (sv)
MX (1) MX9603291A (sv)
NO (1) NO313882B1 (sv)
NZ (1) NZ279265A (sv)
TW (1) TW414801B (sv)
WO (1) WO1995021855A1 (sv)
YU (1) YU7195A (sv)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998630A (en) * 1995-10-10 1999-12-07 Eli Lilly And Company Carbodiimide coupling reagent
US6037363A (en) * 1994-02-11 2000-03-14 Zeneca Limited Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
US20080176883A1 (en) * 2006-11-17 2008-07-24 George Dawn M Aminopyrrolidines as chemokine receptor antagonists

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
GB9502152D0 (en) * 1995-02-03 1995-03-29 Zeneca Ltd Proline derivatives
ES2217404T3 (es) * 1996-03-28 2004-11-01 Glaxo Group Limited Derivados de pirrolopirrolona como inhibidores de la elastasa de neutrofilos.
GB9719187D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
PE107899A1 (es) * 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
GB9719172D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
EP1539710B1 (en) 2002-09-10 2010-10-27 Bayer Schering Pharma Aktiengesellschaft Heterocyclic derivatives
WO2005080372A1 (en) 2004-02-19 2005-09-01 Bayer Healthcare Ag Dihydropyridinone derivatives
DE102005037791A1 (de) * 2005-08-10 2007-02-15 Ernst-Moritz-Arndt Universität Greifswald Verwendung von spezifischen Trifluormethylketonen zur Vorbeugung und Behandlung einer Pankreatitis
CN103226756A (zh) * 2013-04-28 2013-07-31 文俊 工艺品生产过程的工艺制作及生产过程的记录方法和系统
EP4031138A1 (en) 2019-09-17 2022-07-27 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
AU2021256835A1 (en) 2020-04-16 2022-10-13 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189305A2 (en) * 1985-01-22 1986-07-30 Ici Americas Inc. Peptide derivatives
EP0276101A2 (en) * 1987-01-19 1988-07-27 Ici Americas Inc. Substituted peptide derivatives
US5055450A (en) * 1985-01-22 1991-10-08 Ici Americas Inc. Peptide derivatives
US5194588A (en) * 1985-01-22 1993-03-16 Ici Americas Inc. Aminoalcohol intermediates for peptide derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402680D0 (en) * 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189305A2 (en) * 1985-01-22 1986-07-30 Ici Americas Inc. Peptide derivatives
US4910190A (en) * 1985-01-22 1990-03-20 Ici Americas Inc. Peptide derivatives
US5055450A (en) * 1985-01-22 1991-10-08 Ici Americas Inc. Peptide derivatives
US5194588A (en) * 1985-01-22 1993-03-16 Ici Americas Inc. Aminoalcohol intermediates for peptide derivatives
US5414132A (en) * 1985-01-22 1995-05-09 Zeneca Inc. 1-alkyl-2-hydroxy-2-trifluoromethyl ethylamines
EP0276101A2 (en) * 1987-01-19 1988-07-27 Ici Americas Inc. Substituted peptide derivatives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
J. Medicinal Chemistry (1992) 35(4), 641 662. *
J. Medicinal Chemistry (1992) 35(4), 641-662.
J. Mol. Biol. (1988), 201(2), 423 8. *
J. Mol. Biol. (1988), 201(2), 423-8.
Tetrahedron Lett. (1992), 33(30), 4279 82. *
Tetrahedron Lett. (1992), 33(30), 4279-82.
Tetrahedron: Asymmetry (1994), 5(2), 195 8. *
Tetrahedron: Asymmetry (1994), 5(2), 195-8.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037363A (en) * 1994-02-11 2000-03-14 Zeneca Limited Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
US5998630A (en) * 1995-10-10 1999-12-07 Eli Lilly And Company Carbodiimide coupling reagent
US6126932A (en) * 1995-10-10 2000-10-03 Eli Lilly And Company Polymer bound carbodiimide coupling reagent
US20080176883A1 (en) * 2006-11-17 2008-07-24 George Dawn M Aminopyrrolidines as chemokine receptor antagonists
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists

Also Published As

Publication number Publication date
AU692515B2 (en) 1998-06-11
FI963132A0 (sv) 1996-08-09
CN1140455A (zh) 1997-01-15
NO963329L (no) 1996-10-09
EP0743953B1 (en) 1998-12-02
EP0743953A1 (en) 1996-11-27
DK0743953T3 (da) 1999-08-16
NZ279265A (en) 1998-01-26
ES2125004T3 (es) 1999-02-16
TW414801B (en) 2000-12-11
NO963329D0 (no) 1996-08-09
FI963132A (sv) 1996-08-09
AU1583995A (en) 1995-08-29
YU7195A (sh) 1998-09-18
NO313882B1 (no) 2002-12-16
DE69506380D1 (de) 1999-01-14
JP3416142B2 (ja) 2003-06-16
MX9603291A (es) 1997-02-28
JPH09508902A (ja) 1997-09-09
HK1011033A1 (en) 1999-07-02
US5907043A (en) 1999-05-25
GB9402680D0 (en) 1994-04-06
IL112613A (en) 2000-02-29
CA2180006A1 (en) 1995-08-17
IL112613A0 (en) 1995-05-26
US6037363A (en) 2000-03-14
DE69506380T2 (de) 1999-05-06
ATE174034T1 (de) 1998-12-15
WO1995021855A1 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
US5739157A (en) Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
US5965692A (en) Prodrugs of thrombin inhibitors
US5486529A (en) Certain pyridyl ketones for treating diseases involving leukocyte elastase
US5441960A (en) 1-pyrimidinylacetamide human leukocyte elastate inhibitors
US5686628A (en) Proline derivatives
US5521179A (en) Heterocyclic amides
EP0509769A2 (en) Heterocyclic amides having HLE inhibiting activity
WO1993024519A1 (en) Lactam dipeptides having hle inhibiting activity
JPH10500992A (ja) 新しいエラスターゼ阻害剤
CA2070983A1 (en) Cyclic renin inhibitors
CA2070978A1 (en) Cyclic renin inhibitors
AU696292B2 (en) Acylated enol derivatives as prodrugs of elastase inhibitors
MXPA97005231A (en) Prolin derivatives useful as inhibitors of elastase leukocyte hum
TW585853B (en) Novel tripeptide compounds as inhibitors of trypsin-like serine proteases, process for preparation and pharmaceutical composition thereof
JP2001089498A (ja) トロンビン阻害剤のプロドラッグ

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZENECA LIMITED, ENGLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PEGG, STEPHEN JOHN;SEPENDA, GEORGE JOSEPH;DAVIES, ELWYN PETER;AND OTHERS;REEL/FRAME:008220/0131;SIGNING DATES FROM 19960625 TO 19960708

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20060414